Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 23713908.
- Also identified by DOI 10.1164/rccm.201303-0522WS and PMC identifier 3778734.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened the Cell Therapy for Lung Disease Working Group on November 13-14, 2012, to review and formulate recommendations for future research directions. The workshop brought together investigators studying basic mechanisms and the roles of cell therapy in preclinical models of lung injury and pulmonary vascular disease, with clinical trial experts in cell therapy for cardiovascular diseases and experts from the NHLBI Production Assistance for Cell Therapy program. The purpose of the workshop was to discuss the current status of basic investigations in lung cell therapy, to identify some of the scientific gaps in current knowledge regarding the potential roles and mechanisms of cell therapy in the treatment of lung diseases, and to develop recommendations to the NHLBI and the research community on scientific priorities and practical steps that would lead to first-in-human trials of lung cell therapy.
Medical subject headings
- Biomedical Research
- Cell- and Tissue-Based Therapy
- Lung Diseases
- National Heart, Lung, and Blood Institute (U.S.)